Skip to Content

Koninklijke Philips NV ADR PHG

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Philips Still Addressing Issues Over Sleep Devices; Imaging Sees Healthy Demand; Maintaining FVE

Javier Correonero Equity Analyst

Analyst Note

| Javier Correonero |

There were no surprises in narrow-moat Philips' third-quarter results, with sales declining 7.60% organically (EUR 4.20 billion) mainly due to recall issues on its sleep-device installed base. During the second quarter, the company identified potential risks for consumers related to some foams used in their sleep apnea installed base. Of the 2.20 million devices affected, Philips has already produced 750,000 repair kits and replacement devices, of which 250,000 have already reached customers with an expectation to address all affected devices within 12 months from U.S. Food and Drug Administration approval, or September 2022. We forecast a double-digit decline in connected care sales for 2021, only reaching 2020 levels by 2023, and implying a market share loss against Resmed, the main beneficiary of Philips’ issues. Management adjusted its 2021 guidance, but maintained midterm guidance of mid-single-digit growth and 60 to 80 basis points of yearly margin improvement. We have slightly adjusted our midterm margin forecasts, but maintain our EUR 42 fair value estimate.

Read Full Analysis

Company Profile

Business Description

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 44% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (24% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2020, Philips generated EUR 19.5 billion of sales and had 80,000 employees in over 100 countries.

Philips Center, Amstelplein 2
Amsterdam, 1096 BC, Netherlands
T +31 205977777
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 77,746